{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-267697","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.705189+00:00","generated_at":"2026-06-09T02:07:25.549261+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aldeyra grants AbbVie exclusive option to co-develop reproxalap; $1M upfront, $100M upon exercise","bullets":["AbbVie pays $1M non-refundable option fee; can extend option for $5M if FDA decision delayed past Dec 15, 2023.","Upon exercise, AbbVie pays $100M upfront (less prior payments); Aldeyra eligible for up to ~$300M in regulatory and commercial milestones.","In the US, profits/losses split 60% AbbVie, 40% Aldeyra; outside US, Aldeyra receives tiered royalties on net sales.","AbbVie gets right of first negotiation on Aldeyra's other ocular surface compounds and data review rights.","Option expires Dec 23, 2023 if not exercised or extended; tied to FDA decision on reproxalap NDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-267697","json":"https://secwatch.observer/filing/0001193125-23-267697.json","markdown":"https://secwatch.observer/filing/0001193125-23-267697.md","text":"https://secwatch.observer/filing/0001193125-23-267697.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000119312523267697/0001193125-23-267697-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000119312523267697/d857697d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T02:07:25.549261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bd11b9fa5277e90b0ca5b571a923507fe6abd873","claim":"Aldeyra Therapeutics, Inc. entered into Option Agreement with AbbVie Inc. valued at $1 million (effective 2023-10-31).","evidence_excerpt":"On October 31, 2023 (the “Effective Date”), Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) entered into an exclusive option agreement (the “Option Agreement”) with AbbVie Inc. (“AbbVie”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312523267697/0001193125-23-267697-index.htm","confidence":0.85,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"AbbVie Inc."},{"label":"Value","value":"$1 million"},{"label":"Effective","value":"2023-10-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}